Welcome to Kazia

MENU

CEO, Dr James Garner’s presentation to H.C. Wainwright 22^nd Annual Global Investment Conference watch here

CEO, Dr James Garner discusses our recent significant milestones for paxalisib with Share Cafe click here

Dr Matt Dun, and CEO, Dr James Garner discuss the development of paxalisib for DIPG on Channel 7’s Sunrise watch here

Kazia is collaborating with leading research institutes and hospitals to bring new patient therapies to life read more

Learn why paxalisib is a novel potential treatment for glioblastoma brain cancer read more

Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.

News

..

More News
Insights

28-Sep-2020

CEO, Dr James Garner interviewed by Share Café on Dana Farber collaboration

26-Aug-2020

CEO, Dr James Garner interviewed on Share Café

18-Aug-2020

Leading Australian cancer researcher, Dr Matt Dun, interviewed on Channel 7’s Sunrise

More Insights
Resources

5-JAN-2021 New

HC Wainwright: A Unique PI3K Inhibitor for Brain Tumors; Initiate With Buy and $17 PT

15-DEC-2020

Bell Potter: Kazia Therapeutics - Paxalisib Joins A Second Platform Study

10-DEC-2020

Edison Research: Kazia Therapeutics - Cantrixil final Phase I data reported

2-Nov-2020

Bell Potter: Kazia Therapeutics - GBM Agile In More Detail

14-OCT-2020

Corporate Connect: Kazia Therapeutics - A Laser-Like Focus on Adding Value - 5 Data Readouts in 9-Months
Share Price

Historical Prices

SITE BY SPATIAL DESIGN